Flow Cytometry
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage and reimbursement rules for flow cytometry testing, including immunophenotyping and DNA/ploidy/S-phase analyses, and the clinical indications and limitations that govern payment by the payer.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Covered Indications (Immunophenotyping)
Flow cytometry immunophenotyping MEETS COVERAGE CRITERIA for any of the following:
Each listed indication is sufficient per policy.
The policy excludes routine measurement of flow cytometry–derived DNA content (DNA Index) or cell proliferative activity (S-phase fraction or % S-phase) when used for prognostic or therapeutic purposes in the routine clinical management of cancers. This exclusion reflects the absence of sufficient published evidence that DNA ploidy or flow-cytometric proliferation metrics are required and beneficial for guiding diagnosis or treatment decisions in standard oncology practice.
Professional society guidance cited in the policy recommends against routine clinical use of DNA ploidy or S-phase fraction for prognosis in several tumor types. ASCO guidance states that flow-cytometrically derived DNA ploidy and % S-phase should not be used to determine prognosis for early-stage colorectal cancer and found insufficient evidence to support routine use in breast cancer. NCCN guidelines for multiple solid tumors do not reference S-phase fraction as a management tool, and ISGyP notes a lack of definitive studies supporting routine ploidy analysis in endometrial carcinoma.
The policy includes literature citations and consensus recommendations that inform the clinical context for flow cytometry and cell cycle analyses. References include the 2006 Bethesda Consensus for hematolymphoid immunophenotyping and multiple clinical studies and reviews on DNA ploidy, cell proliferation markers, and flow cytometry applications. The document’s references and an adoption note provide supporting background but do not list additional explicit coverage exclusions beyond those stated elsewhere in the policy.
In summary, routine use of flow cytometry–derived DNA ploidy or S-phase fraction for prognostic or therapeutic decision-making in cancer is not supported by this policy. The policy states that these measurements do not meet coverage criteria for routine clinical cancer management because available evidence does not demonstrate consistent clinical utility for standard prognostic or treatment decisions.
Within the cited material there are no separate, explicit sections declaring additional tests as universally 'not medically necessary' beyond the DNA ploidy/S-phase coverage position; the policy primarily documents literature references and consensus guidance used to support coverage determinations.
Covered Indications for Flow Cytometry
inv-32: Immunophenotyping for hematologic malignancies, immunodeficiencies, transplant monitoring, MRD per related MRD policy, and certain non-neoplastic blood disorders.
Immunophenotyping is covered for hematologic malignancies, immunodeficiencies, transplant monitoring, MRD per referenced MRD policy, and selected non-neoplastic blood disorders when clinical indication is documented:
Ordering must document one of the covered indications; panel selection should follow specimen type, clinical information, and morphology per Bethesda recommendations.
inv-33: Immunophenotyping for hematolymphoid neoplasia, acute leukemia workup, and platelet disorder assessment
Immunophenotyping is covered in these hematolymphoid and platelet disorder contexts when testing and panels are selected per consensus guidance:
Follow Bethesda, CAP/ASH, and ISTH guidance for panel composition and use; when marrow or peripheral blood is insufficient for FCI, immunohistochemistry or repeat sampling may be used.
inv-34: Diagnostic, prognostic, and monitoring use of flow cytometry and DNA ploidy/cell cycle analysis in hematologic neoplasms and selected solid tumors.
Flow cytometry and, separately, DNA ploidy/cell-cycle analyses have diagnostic, prognostic, and monitoring roles supported by cited literature, but use of DNA ploidy/S-phase for routine prognostic or therapeutic decisions is limited by guidance:
These uses are supported by the citations listed; clinical adoption should follow guideline recommendations and institutional validation.
See exclusions and not-covered sections for specifics and referenced studies.
Coding and Reimbursement
Provider Actions, Documentation, and Lab Requirements
Prior authorization / coverage overview
Flow cytometry immunophenotyping for the listed hematologic, immunologic, transplant monitoring, primary immunodeficiency, MRD (per referenced MRD policy), and related indications is subject to the coverage and coding rules below. There are no explicit prior-authorization denials specified in this section.
- No explicit denial triggers are stated in these source chunks.
Documentation and coding guidance
Claims and clinical documentation should clearly state the covered indication for testing and include relevant clinical information (specimen type, clinical history, morphology). Use the specified flow cytometry CPT/HCPCS codes for billing and follow unit limits and bundling rules.
- Use codes 88184-88189 for immunophenotyping related to hematolymphoid neoplasia.
- Code 88184 = first marker per specimen (reimbursable up to 2 units per date of service).
- Code 88185 = each additional marker (reimbursable up to 35 units per date of service).
- Codes 88187-88189 reimbursed at one unit per specimen, up to two specimens per date of service; do not use 88187-88189 together for a single specimen in any combination.
- Do not bill 88187-88189 in conjunction with 86355, 86356, 86357, 86359, 86360, 86361, or 86367.
- Use codes 86355, 86357, 86359, 86360, 86361, or 86367 for cell enumeration (single unit only).
Panel selection guidance
Selection of initial and secondary reagent panels should be based on specimen type (peripheral blood, bone marrow, tissue, etc.), available clinical information, and cell morphology. Initial panels range from 4 to 12 reagents; secondary panels (when initial evaluation is inconclusive) may range from 5 to 23 reagents. For neoplasms with an established immunophenotype, subsequent testing should be limited to diagnostically relevant markers.
- Choose panels per Bethesda 2006 recommendations: specimen type, clinical info, morphology guide panel size and markers.
- Limit follow-up testing in known neoplasms to relevant markers.
LDT validation and CLIA
Laboratory-developed tests (LDTs) used for flow cytometry are regulated under CLIA as high-complexity tests and must be validated by the performing laboratory. These tests are not FDA-cleared or -approved for clinical use in many cases; however, FDA clearance is not currently required for clinical use.
- LDTs must meet CLIA '88 validation requirements.
- Document that in‑house assays have appropriate validation records when applicable.
Transfer of laboratory data on referral
If a patient is referred to another institution for treatment, provide the receiving site with all laboratory results, pathology slides, flow cytometry data, cytogenetic information, and a list of pending tests at time of referral. Forward pending test results when they become available.
- Ensure transfer of all flow cytometry raw data and reports on referral.
No step therapy requirements
There are no step-therapy requirements specified for flow cytometry in these source chunks.
- No step therapy is required.
DNA ploidy / S‑phase not covered
Flow cytometry–derived DNA ploidy or S‑phase fraction measurements for prognostic or therapeutic purposes in routine clinical cancer management do not meet coverage criteria due to insufficient evidence.
- DNA Index or %S‑phase testing is NOT covered for routine prognostic/therapeutic use.
Supporting literature and guidance
This section is supported by relevant literature and consensus guidance, including the 2006 Bethesda International Consensus recommendations and subsequent peer-reviewed studies and society guidelines. See the bibliography for citations informing indications, panel selection, and technical considerations.
- Davis et al., 2007 — 2006 Bethesda International Consensus recommendations.
- Selected peer-reviewed studies and society guidance on flow cytometry standardization, platelet/immune monitoring, Hodgkin lymphoma diagnosis, and MRD applications.
Government policy precedence
When government policies (Local Coverage Determinations, National Coverage Determinations, or state Medicaid rules) conflict with this policy, the applicable government policy takes precedence for the affected member.
- Follow LCDs, NCDs, and state Medicaid coverage when applicable.
(Placeholder) No additional provider-action content specified in source chunks.
Ordering Requirements
Ordering requirements — order only for listed covered indications; follow MRD policy for MRD testing
Orders for flow cytometry must reflect one of the covered clinical indications listed in the policy; MRD testing coverage is permitted only if consistent with the referenced MRD policy.
- Ensure the clinical indication on the order matches a listed covered condition (e.g., cytopenias, suspected lymphoma/leukemia, transplant monitoring, PIDs).
- For MRD, confirm alignment with Avalon Policy AHS-M2175-Minimal Residual Disease.
Ordering requirements — choose reagent panels by specimen, clinical info, and morphology
Select reagents and panels based on the specimen type, clinical information, and cell morphology; initial panels (4–12 reagents) and secondary panels (5–23 reagents) should follow Bethesda recommendations for the specific indication.
- Tailor panel selection to the clinical question and specimen (peripheral blood, bone marrow, tissue, body fluid).
- Use secondary panels when initial evaluation is inconclusive.
Ordering requirements — no provider restrictions specified
The policy does not specify any restrictions on which providers may order flow cytometry testing in the referenced sections.
- No ordering provider limitations are stated in the cited policy excerpts.
Not Covered
Flow cytometry–derived DNA index and S-phase fraction testing for routine prognostic or therapeutic use in cancer is designated in the policy as not meeting coverage criteria. Providers should expect such testing for routine prognostic or treatment decisions to be excluded from coverage based on the policy’s stated stance and the referenced professional guidance.
The policy specifically cites professional recommendations that do not support routine flow-cytometric DNA ploidy or S-phase fraction use for prognosis in early-stage colorectal cancer and breast cancer, and notes insufficient evidence for routine ploidy analysis in endometrial carcinoma. These tumor-specific guidance statements are referenced as part of the rationale for noncoverage of routine prognostic use.
The referenced chunks do not enumerate additional, test-specific exclusions beyond the DNA ploidy/S-phase statements; they primarily provide supporting literature citations that informed the policy’s coverage conclusions.
Definitions
Frequency and Unit Limits
Background
Flow cytometry is a laboratory technique for live cell analysis that measures optical light scattering and fluorescence to determine cellular characteristics such as size, granularity, viability, and biomarker expression. The method enables enumeration of cell populations and identification of surface and intracellular markers for applications including immunophenotyping, diagnosis and monitoring of hematologic malignancies, transplant monitoring, primary immunodeficiencies, and minimal residual disease when covered by the referenced MRD policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.